Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 12;14:1108682. doi: 10.3389/fimmu.2023.1108682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Ayoub, Dauvilliers, Barateau, Vermeulen, Mouton-Barbosa, Marcellin, Gonzalez-de-Peredo, Gross, Saoudi and Liblau

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The complement and coagulation pathway are enriched in NT1 patients. (A) The proteins involved in the complement and coagulation pathway, their log2 fold change ratio in cohort 1. (B) The proteins involved in the complement and coagulation pathway, their log2 fold change ratio in cohort 2. (A, B) The proteins that are significantly regulated in the CSF of NT1 patients are indicated with a star (p-value<0.05; Limma test). (C) Boxplots of the differentially regulated proteins in cohort 1. (D) Boxplots of selected proteins in cohort 2. *p-value<0.05, **p-value <0.01; Mann Whitney test. (E) Complement and coagulation proteins differentially regulated in both cohort 1 and cohort 2 and their log2 fold change. (F) Representation of the complement and coagulation proteins highlighting in red proteins up-regulated in the CSF of NT1 patients from both cohorts.